National Academy To Close Issues

WASHINGTON—Financial problems have claimed another victim in the science publishing field. The National Academy of Sciences has decided to fold its quarterly journal, Issues in Science and Technology. "Issues just hasn't been able to attract the audience needed to make it financially successful," said Pepper Leeper, a spokeswoman for the Academy. "It never really broke even," she added, declining to release figures. The 2 ½-year-old journal, aimed at scientists and an informed public,

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

"Issues just hasn't been able to attract the audience needed to make it financially successful," said Pepper Leeper, a spokeswoman for the Academy. "It never really broke even," she added, declining to release figures.

The 2 ½-year-old journal, aimed at scientists and an informed public, has a circulation of approximately 10,000—including just under 9,000 paid subscriptions at $36 per year for individuals or $56 for institutions. Advertising, while welcome, has been scant.

The news of the closing has generated a "small amount of interest" by other organizations looking to take over the publication, Leeper said, but no serious discussions have taken place. The Academy itself is considering other media-related activities similar to its recent "Planet Earth" series done in cooperation with public television.

Two more issues of the journal are planned, she said, the spring issue in early March and the summer issue in early June.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies